BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 17611687)

  • 1. Prediction of risk of disease recurrence by genome-wide cDNA microarray analysis in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy.
    Zembutsu H; Yanada M; Hishida A; Katagiri T; Tsuruo T; Sugiura I; Takeuchi J; Usui N; Naoe T; Nakamura Y; Ohno R
    Int J Oncol; 2007 Aug; 31(2):313-22. PubMed ID: 17611687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
    Ottmann OG; Wassmann B; Pfeifer H; Giagounidis A; Stelljes M; Dührsen U; Schmalzing M; Wunderle L; Binckebanck A; Hoelzer D;
    Cancer; 2007 May; 109(10):2068-76. PubMed ID: 17429836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lee S; Kim YJ; Chung NG; Lim J; Lee DG; Kim HJ; Min CK; Lee JW; Min WS; Kim CC
    Cancer; 2009 Feb; 115(3):561-70. PubMed ID: 19117346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
    Yanada M; Takeuchi J; Sugiura I; Akiyama H; Usui N; Yagasaki F; Kobayashi T; Ueda Y; Takeuchi M; Miyawaki S; Maruta A; Emi N; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
    J Clin Oncol; 2006 Jan; 24(3):460-6. PubMed ID: 16344315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.
    Pfeifer H; Wassmann B; Hofmann WK; Komor M; Scheuring U; Brück P; Binckebanck A; Schleyer E; Gökbuget N; Wolff T; Lübbert M; Leimer L; Gschaidmeier H; Hoelzer D; Ottmann OG
    Clin Cancer Res; 2003 Oct; 9(13):4674-81. PubMed ID: 14581336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy.
    Yanada M; Sugiura I; Takeuchi J; Akiyama H; Maruta A; Ueda Y; Usui N; Yagasaki F; Yujiri T; Takeuchi M; Nishii K; Kimura Y; Miyawaki S; Narimatsu H; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
    Br J Haematol; 2008 Nov; 143(4):503-10. PubMed ID: 18986386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of imatinib mesylate as maintenance therapy in adults with acute lymphoblastic leukemia in first complete remission.
    Potenza L; Luppi M; Riva G; Marasca R; Martinelli S; Torelli G
    Haematologica; 2005 Sep; 90(9):1275-7. PubMed ID: 16154854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Acute lymphoblastic leukemias with aberrations of BCR-ABL genes].
    Parovichnikova EN; Savchenko VG; Verniuk MA; Vinogradova OA; Misiurin AV; Vorob'ev IA; Domracheva EV; Tikhonova LIu; Rukavitsyn OA; Rossiev VA; Kliasova GA; Turkina AG; Liubimova LS; Mendeleeva LP; Isaev VG
    Ter Arkh; 2005; 77(7):11-6. PubMed ID: 16116902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical study of Philadelphia chromosome-positive adult acute lymphoblastic leukemia].
    Zhang YF; Chen ZM; Lou JY; Ni WM; Wang YG; Meng HT; Tong HY; Qian WB; Jin J
    Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):814-8. PubMed ID: 22339953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of response to imatinib by cDNA microarray analysis.
    Ohno R; Nakamura Y
    Semin Hematol; 2003 Apr; 40(2 Suppl 2):42-9. PubMed ID: 12783375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of elderly patients with acute lymphoblastic leukemia--evidence for a benefit of imatinib in BCR-ABL positive patients.
    Brandwein JM; Gupta V; Wells RA; Schuh AC; Schimmer AD; Lipton JH; Messner HA; Yi QL; Chun K; Kamel-Reid S; Minden MD
    Leuk Res; 2005 Dec; 29(12):1381-6. PubMed ID: 15927253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Successful induction and long-term molecular remission with imatinib mesylate and chemotherapy in a case of Ph-positive acute lymphoblastic leukemia].
    Hirayama Y; Sakamaki S; Takayanagi N; Tsuji Y; Sagawa T; Chiba H; Maeda M; Matsunaga T; Kato J; Niitsu Y
    Rinsho Ketsueki; 2003 May; 44(5):334-8. PubMed ID: 12822409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients.
    Piccaluga PP; Malagola M; Amabile M; Rondoni M; Paolini S; Pane F; Russo D; Visani G; Baccarani M; Martinelli G
    Haematologica; 2004 Oct; 89(10):1269-71. PubMed ID: 15477218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Additional chromosomal abnormalities and their prognostic significance in adult Philadelphia-positive acute lymphoblastic leukemia: with or without imatinib in chemotherapy.
    Li Y; Qiu L; Zou D; Zhao Y; Mi Y; Wang J
    Ann Hematol; 2009 Nov; 88(11):1069-77. PubMed ID: 19277658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy.
    Yanada M; Takeuchi J; Sugiura I; Akiyama H; Usui N; Yagasaki F; Nishii K; Ueda Y; Takeuchi M; Miyawaki S; Maruta A; Narimatsu H; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
    Haematologica; 2008 Feb; 93(2):287-90. PubMed ID: 18223280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anterior chamber infiltration in a patient with Ph+ acute lymphoblastic leukemia in remission with imatinib.
    Hurtado-Sarrió M; Duch-Samper A; Taboada-Esteve J; Martínez-Dominguez JA; Senent-Peris ML; Menezo-Rozalén JL
    Am J Ophthalmol; 2005 Apr; 139(4):723-4. PubMed ID: 15808178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.
    Martinelli G; Iacobucci I; Storlazzi CT; Vignetti M; Paoloni F; Cilloni D; Soverini S; Vitale A; Chiaretti S; Cimino G; Papayannidis C; Paolini S; Elia L; Fazi P; Meloni G; Amadori S; Saglio G; Pane F; Baccarani M; Foà R
    J Clin Oncol; 2009 Nov; 27(31):5202-7. PubMed ID: 19770381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lee S; Kim DW; Cho BS; Yoon JH; Shin SH; Yahng SA; Lee SE; Eom KS; Kim YJ; Chung NG; Kim HJ; Min CK; Lee JW; Min WS; Park CW
    Leukemia; 2012 Nov; 26(11):2367-74. PubMed ID: 22705993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL).
    Burke MJ; Cao Q; Trotz B; Weigel B; Kumar A; Smith A; Verneris MR
    Pediatr Blood Cancer; 2009 Dec; 53(7):1289-94. PubMed ID: 19731318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response.
    Qin YZ; Liu YR; Zhu HH; Li JL; Ruan GR; Zhang Y; Jiang Q; Jiang H; Li LD; Chang Y; Huang XJ; Chen SS
    Int J Lab Hematol; 2008 Aug; 30(4):317-23. PubMed ID: 18665830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.